We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
For the second time, a federal appeals court has invalidated a GlaxoSmithKline
(GSK) patent for the antidepressant Paxil, a decision that reaffirms Apotex's
move to launch a generic version of the drug more than a year ago.
GlaxoSmithKline (GSK) has finalized a deal to market a prescription version
of Roche's leading weight-loss drug Xenical in the U.S., the companies said.
Wholesale prices of common brand drugs are rising much faster than the rate
of inflation, concludes an AARP report, which was promptly countered by PhRMA
officials, who contend that drug prices are growing at a slower rate than overall
healthcare costs.
Icoria Inc. announced that it will use its metabolomics and gene expression
methodologies to characterize ADMET Technologies, Inc.'s human adult hepatocytes,
to improve their value as a predictive toxicology screening tool in the early
stages of drug development.
UK chemicals group Avecia is planning to close its biotechnology center at Grangemouth,
Scotland, by the end of the summer, resulting in the loss of 95 jobs, reports
Phil Taylor.
SkyePharma PLC announced that it has entered into a strategic development and
marketing arrangement with Mundipharma International Holdings Limited (Mundipharma)
for the marketing and distribution of DepoBupivacaine in Europe and other international
markets excluding the USA, Canada and Japan. Mundipharma is already SkyePharma's
European marketing partner for the cancer treatment DepoCyte.
Matrix Laboratories Ltd has received U.S. FDA approval for its Active Pharmaceutical
Ingredients (APIs) manufacturing facility located at Kazipally (Unit-II), near
Hyderabad.
Solutia has elected to retain its Pharmaceutical Services Division (PSD) despite
suggestions that a spin out or sale of the business were being considered, reports
Phil Taylor.
Jazz Pharmaceuticals, Inc. and Orphan Medical, Inc. announced that they have
entered into an agreement and plan of merger pursuant to which Jazz Pharmaceuticals,
through a wholly owned subsidiary, will acquire Orphan Medical.